

PB1825 IDENTIFYING GENE TARGETS FOR DRUG REPURPOSING TO COUNTER MYELOID LEUKEMIA IN CHILDREN WITH DOWN-SYNDROME (ML-DS)

Topic: 3. Acute myeloid leukemia - Biology & Translational Research

Anna-Lena Schmall^{*1}, Kristof Meier², Oriol Alejo-Valle², Dirk Heckel², Raj Bhayadia¹, Jan-Henning Klusmann¹

¹Department Of Pediatrics, Goethe University Frankfurt, Frankfurt Am Main, Germany; ²Pediatric Hematology And Oncology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

Background:

Transient abnormal myelopoiesis (TAM) is a preleukemic disorder that affects 30% of newborns with Down syndrome, which can progress to myeloid leukemia (ML-DS). The current lack of effective treatments for TAM is due to limited clinical trials and the high sensitivity of trisomy 21 patients to chemotherapeutic toxicity. Preventing the progression from TAM to ML-DS remains a significant challenge.

Aims:

Our goal is to identify treatment options to prevent the progression from TAM to ML-DS by repurposing FDA-approved therapeutics.

Methods:

We created an aggressive TAM-like state in murine hematopoietic cells by overexpressing oncogenes located on chromosome 21 to model the genetic origin of ML-DS. We then conducted CRISPR-Cas9 knockout screens, targeting only genes connected to FDA-approved therapeutics, and integrated these findings with ML-DS cell line data. We used single knockout proliferation assays for validation and compared our results to the currently used treatment.

Results:

Our approach revealed over 30 candidates, with seven genes found to be directly connected in the same pathway. Patient-derived gene expression data and validation in the murine model and leukemic cell lines led to several promising therapeutics. In vitro drug testing of two drugs yielded particularly promising results, individually and when compared to the current treatment.

Summary/Conclusion:

Our approach of repurposing existing drug targets has led to the discovery of alternative treatments for TAM patients, advancing our long-term goal of preventing cancer in children with a premalignant state. By focusing on the underlying genetic mechanisms, we have increased treatment options, potentially reducing the toxicity burden for TAM patients.

Copyright Information: (Online) ISSN: 2572-9241

© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2023;7(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.